Pembrolizumab for Ovary Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Princess Margaret Cancer Centre, Toronto, Canada
Ovary Cancer+7 More
Pembrolizumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).

Eligible Conditions

  • Ovary Cancer
  • Ovarian Cancer
  • Small Cell Carcinoma, Hypercalcaemic Type

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Ovary Cancer

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 2 years

2 Years
Exploratory Endpoint
2 years
Objective evidence of response to treatment
Progression free survival
overall performance status

Trial Safety

Safety Progress

1 of 3

Other trials for Ovary Cancer

Side Effects for

Pembrolizumab + Etoposide
54%Neutropenia
45%Anaemia
38%Nausea
34%Alopecia
31%Decreased appetite
29%Constipation
27%Fatigue
26%Thrombocytopenia
22%Leukopenia
20%Cough
20%Diarrhoea
17%Asthenia
17%Dyspnoea
16%Vomiting
14%Pyrexia
14%Dizziness
13%Rash
13%Headache
11%Insomnia
11%Pruritus
11%Back pain
10%Hypothyroidism
10%Weight decreased
9%Arthralgia
9%Hyponatraemia
9%Aspartate aminotransferase increased
8%Oedema peripheral
8%Alanine aminotransferase increased
8%Pneumonia
7%Abdominal pain
7%Upper respiratory tract infection
7%Blood creatinine increased
7%Hypokalaemia
7%Febrile neutropenia
6%Hyperthyroidism
6%Abdominal pain upper
6%Stomatitis
6%Dysgeusia
6%Dry skin
5%Dyspepsia
5%Dysphagia
5%Chest pain
5%Blood alkaline phosphatase increased
5%Musculoskeletal pain
5%Erythema
5%Hypertension
5%Nasopharyngitis
5%Musculoskeletal chest pain
5%Pain in extremity
4%Hypotension
2%Death
2%Acute kidney injury
2%Pneumonitis
2%Pulmonary embolism
2%Atrial fibrillation
1%Neutropenic sepsis
1%Inappropriate antidiuretic hormone secretion
1%Diabetes mellitus
1%Hemiparesis
1%Transient ischaemic attack
1%Superior vena cava syndrome
1%Pneumothorax
1%Gastritis
1%Aortic aneurysm
1%Sepsis
1%Pleural infection
1%Infusion related reaction
1%Clostridium difficile colitis
1%Urinary tract infection
0%Empyema
0%Pneumonia haemophilus
0%Escherichia sepsis
0%Pseudomonas infection
0%Cardiopulmonary failure
0%Myocarditis
0%Acute coronary syndrome
0%Tooth infection
0%Vertigo
0%Secondary adrenocortical insufficiency
0%Myocardial infarction
0%Vitreous haemorrhage
0%Hypopituitarism
0%Gastrointestinal viral infection
0%Diverticulum
0%Infective exacerbation of chronic obstructive airways disease
0%Food poisoning
0%Cholecystitis
0%Diverticulitis
0%Cholecystitis infective
0%Appendicitis
0%Hepatotoxicity
0%Lower respiratory tract infection
0%Spinal fracture
0%Serratia sepsis
0%Fall
0%Joint injury
0%Femur fracture
0%Skin laceration
0%Gouty arthritis
0%Dehydration
0%Type 1 diabetes mellitus
0%Spinal osteoarthritis
0%Paraneoplastic syndrome
0%Cognitive disorder
0%Cancer pain
0%Tremor
0%Aphasia
0%Cerebrovascular accident
0%Loss of consciousness
0%Confusional state
0%Prostatitis
0%Benign prostatic hyperplasia
0%Autoimmune nephritis
0%Bronchospasm
0%Chronic obstructive pulmonary disease
0%Epistaxis
0%Haemoptysis
0%Hypoxia
0%Laryngeal haemorrhage
0%Oropharyngeal pain
0%Decubitus ulcer
0%Respiratory failure
0%Embolism
0%Subacute cutaneous lupus erythematosus
0%Deep vein thrombosis
0%Peripheral embolism
0%Hypertensive crisis
0%Pericardial effusion
0%Haematuria
0%Cardiac arrest
0%Haematemesis
0%Bacteraemia
0%Limbic encephalitis
0%Colitis
0%Keratitis
0%Toxic encephalopathy
0%Urosepsis
0%Peripheral motor neuropathy
0%Cardiac failure
0%Proctitis
0%Neurogenic bladder
0%Gastroenteritis
0%Pain
0%Pneumonia aspiration
0%Bronchitis
0%Pleural effusion
0%Peripheral artery occlusion
0%Atypical pneumonia
0%Myositis
0%Paracancerous pneumonia
0%Autoimmune uveitis
0%Herpes zoster
0%Oesophagitis
0%Vena cava thrombosis
0%Influenza
0%Presyncope
0%Hyperglycaemia
This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT03066778) in the Pembrolizumab + Etoposide ARM group. Side effects include: Neutropenia with 54%, Anaemia with 45%, Nausea with 38%, Alopecia with 34%, Decreased appetite with 31%.

Trial Design

1 Treatment Group

Pembrolizumab
1 of 1
Experimental Treatment

1 Total Participants · 1 Treatment Group

Primary Treatment: Pembrolizumab · No Placebo Group · N/A

Pembrolizumab
Drug
Experimental Group · 1 Intervention: Pembrolizumab · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 3
~2670

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
Closest Location: Princess Margaret Cancer Centre · Toronto, Canada
Photo of princess margaret cancer centre 1Photo of princess margaret cancer centre 2Photo of princess margaret cancer centre 3
2021First Recorded Clinical Trial
0 TrialsResearching Ovary Cancer
177 CompletedClinical Trials

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,351 Previous Clinical Trials
471,632 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.